Section
Real-world surveillance from 2024–2025 shows substantial reductions in RSV-associated hospitalizations among infants after broad availability of maternal RSV vaccination and nirsevimab, with effectiveness estimates approximating those from
A phase 1 trial of the rVSV‑vectored Lassa vaccine demonstrated dose-dependent transient reactogenicity, no vaccine‑related serious adverse events or hearing loss, and robust, durable humoral and cellular responses across doses and lineages
A large Asian cohort study shows serum HBsAg <100 IU/mL reliably identifies inactive chronic hepatitis B patients whose annual HCC risk is <0.2%, potentially allowing de‑escalation of surveillance and informing partial HBV cure defini
In the phase 2 REEF‑IT trial, pegylated interferon‑α2a added to siRNA JNJ‑73763989 produced large HBsAg reductions and transient seroclearance in some untreated HBeAg‑positive patients, but no participant reached the prespecified sustained
A multinational cohort study of 1,986 patients with indeterminate chronic hepatitis B (CHB) shows large differences in long‑term hepatocellular carcinoma (HCC) risk by baseline indeterminate subtype and by phase transition, identifying subg
National APSU surveillance (1999–2024) found 479 definite congenital CMV cases and dramatic under-ascertainment versus expected prevalence; symptomatic infants increasingly receive antivirals. Expanded surveillance, newborn screening, and c
This study identifies clinical and demographic factors associated with positive blood cultures in hospitalized children across nine African and Asian countries, aiming to improve diagnostic stewardship amidst resource constraints.
This study assesses the feasibility and performance of using self-collected urine and vaginal samples with the BD Onclarity® HPV assay for cervical cancer screening in Japanese women with abnormal cytology, highlighting concordance and sens
The REPAIR study demonstrates that prophylactic antibiotics reduce clinically relevant wound complications after episiotomy or second degree tears, highlighting a potential role for antibiotics in postpartum care.
A booster dose of the hexavalent group B streptococcus conjugate vaccine (GBS6) administered approximately two years after the primary dose in healthy adults is safe and elicits robust, enhanced immune responses, promising for maternal immu
A novel live attenuated oral vaccine, CVD 1902, shows 73% efficacy against Salmonella Paratyphi A infection in a controlled human challenge model, offering promising protection with a favorable safety profile.
A large international trial found that selective decontamination of the digestive tract (SDD) during mechanical ventilation did not reduce hospital mortality but decreased bloodstream infections and antibiotic-resistant organisms, with no c
A pragmatic randomized trial in Kenyan public hospitals demonstrates that adjunctive low-dose glucocorticoid therapy significantly reduces 30-day mortality in adults with community-acquired pneumonia without increasing serious adverse event
This article reviews two types of flu vaccines for children—live attenuated and inactivated—over 20 years, demonstrating both provide meaningful protection and highlighting improvements that have enhanced their effectiveness.
A systematic review supports the continued safety and effectiveness of Covid-19, RSV, and influenza vaccines for the upcoming 2025-2026 season, highlighting detailed vaccine efficacy, safety profiles, and recommendations for at-risk populat
A comprehensive Singaporean cohort study reveals increased odds of cardiovascular complications during the first 30 days post-acute dengue infection, especially in older adults, emphasizing the need for targeted cardiac monitoring.
A large retrospective cohort study found no significant association between perinatal or early infant antibiotic exposure and subsequent hospitalization for infections in early childhood, providing reassurance about the cautious use of anti
A randomized trial showed rifaximin does not improve 12-month survival or reduce complications in severe cirrhosis with ascites, but better adherence may decrease liver-related events.
This review explores the potential of targeting HBx-induced HSPB1 to suppress HBV cccDNA and enhance hepatic immune responses, highlighting a promising peptide-based therapeutic approach.
A Spanish multicenter study reveals a sharp rise in pediatric invasive group A streptococcal infections and severity after 2022, highlighting emm1 strain predominance and risk factors for critical illness and mortality.
